Staged Mucosal Advancement Flap versus Staged Fibrin Sealant in the Treatment of Complex Perianal Fistulas

Table 1

(a) Patient characteristics of the fistula. (b) patient characteristics.

(a)

	MF	FS
	𝑁=15	𝑁=15
1 fistula track	𝑁=4 (27%)	𝑁=10 (67%)	𝑃=0.15
2 or more fistula tracks	𝑁=11 (73%)	𝑁=5 (33%)	𝑃=0.08
Abscess	𝑁=2 (13%)	𝑁=0 (0%)	𝑃=0.20
Residual inflammation and prolonged seton treatment	𝑁=3 (20%)	𝑁=4 (27%)	𝑃=0.30

(b)

	MF	FS
	𝑁=15	𝑁=15
Sex	Male 𝑁=10(67%)	Male 𝑁=11(73%)	𝑃=0.55
	Female 𝑁=5(33%)	Female 𝑁=4(27%)
Age (years)	51 (range 39–70)	45 (range 30–68)	𝑃=0.48
Median followup (months)	52 (46–60) months	49 (49–59) months	𝑃=0.45
Tobacco smokers	𝑁=6(40%)	𝑁=8(53%)	𝑃=0.30
Soiling (before treatment)	𝑁=2(13%)	𝑁=3(20%)	𝑃=0.40